C Fontaine, S De Brakeleer, E Teugels, V Renard, H Van den Bulck, P Vuylsteke, P. Glorieux, C Dopchie, S Joris, L Decoster, A Awada, K Punie, H Wildiers, J De Grève
{"title":"同源重组核心基因杂合子种系突变可预测早期三阴性乳腺癌的病理完全缓解","authors":"C Fontaine, S De Brakeleer, E Teugels, V Renard, H Van den Bulck, P Vuylsteke, P. Glorieux, C Dopchie, S Joris, L Decoster, A Awada, K Punie, H Wildiers, J De Grève","doi":"10.26502/jbb.2642-91280110","DOIUrl":null,"url":null,"abstract":"Background: BSMO 2014-01 is a published prospective phase 2 study investigating neoadjuvant weekly paclitaxel and carboplatin, followed by epirubicin and cyclophosphamide in 63 patients with triple-negative breast cancer. Pathological complete response (pCR) was 54%. A secondary endpoint was to correlate pCR rate to the presence of germline pathogenic variants in DNA damage response (DDR) genes and in core genes involved in Homologous Recombination (HR).","PeriodicalId":15066,"journal":{"name":"Journal of Biotechnology and Biomedicine","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Heterozygote Germline Mutations in Homologous Recombination Core Genes Can Predict for Pathologic Complete Response in Early Triple Negative Breast Cancer\",\"authors\":\"C Fontaine, S De Brakeleer, E Teugels, V Renard, H Van den Bulck, P Vuylsteke, P. Glorieux, C Dopchie, S Joris, L Decoster, A Awada, K Punie, H Wildiers, J De Grève\",\"doi\":\"10.26502/jbb.2642-91280110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: BSMO 2014-01 is a published prospective phase 2 study investigating neoadjuvant weekly paclitaxel and carboplatin, followed by epirubicin and cyclophosphamide in 63 patients with triple-negative breast cancer. Pathological complete response (pCR) was 54%. A secondary endpoint was to correlate pCR rate to the presence of germline pathogenic variants in DNA damage response (DDR) genes and in core genes involved in Homologous Recombination (HR).\",\"PeriodicalId\":15066,\"journal\":{\"name\":\"Journal of Biotechnology and Biomedicine\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biotechnology and Biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26502/jbb.2642-91280110\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biotechnology and Biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/jbb.2642-91280110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Heterozygote Germline Mutations in Homologous Recombination Core Genes Can Predict for Pathologic Complete Response in Early Triple Negative Breast Cancer
Background: BSMO 2014-01 is a published prospective phase 2 study investigating neoadjuvant weekly paclitaxel and carboplatin, followed by epirubicin and cyclophosphamide in 63 patients with triple-negative breast cancer. Pathological complete response (pCR) was 54%. A secondary endpoint was to correlate pCR rate to the presence of germline pathogenic variants in DNA damage response (DDR) genes and in core genes involved in Homologous Recombination (HR).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
